Ordination Dr Robert Voves

Research site

Austria Bismarckstrasse 4, 8330 Feldbach, Austria

Asthma · Chronic obstructive pulmonary disease
Adults and children

About Specializations

Ordination Dr Robert Voves in Feldbach, Austria specialises in clinical trials of conditions such as Asthma, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Tract Diseases

The Pulmonary department at Ordination Dr Robert Voves focuses on innovative research for respiratory tract diseases, targeting both Chronic Obstructive Pulmonary Disease (COPD) and severe asthma with an eosinophilic phenotype. The aim is to improve patient outcomes by testing new biologic agents and comparing them with existing treatments.

Evaluation of astigolimab for reducing exacerbations in COPD patients.
Non‑inferiority study of GSK3511294 (depemokimab) versus mepolizumab or benralizumab in eosinophilic severe asthma.

With two active trials and a single dedicated investigator, this Austrian site is advancing therapeutic options for individuals living with chronic lung conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Bismarckstrasse 48330 FeldbachAustria

Open in maps ↗

Recruiting now: no trials
Conditions studied: 2

More sites in Feldbach Austria

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

2 clinical trials

Chronic obstructive pulmonary disease

Not recruiting

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Astegolimab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Benralizumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites